FDA Grants Approval for Romidepsin ANDA219099 by Amneal
The FDA has granted approval for Amneal's ANDA219099 for Romidepsin, indicating a successful submission.
Published: July 22, 2026
Updated: July 22, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / HDAC Inhibitor
Asset: Amneal
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Amneal
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Amneal's generic Romidepsin introduces significant competition in the oncology market. This could impact pricing strategies and market share for existing branded products, necessitating close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of Amneal's Romidepsin and any potential pricing strategies from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.